OA
GILD icon

Oasis Advisors’s Gilead Sciences GILD Stock Holding History

Oasis Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,700
Closed -$376K – 114
2026
Q1 		$376K Buy
+2,700
New +$378K 0.07% 143

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Oasis Advisors's GILD Position: Q2 2026 in Review

Oasis Advisors sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 2,700 shares — an estimated $376K sold.

Oasis Advisors first reported a position in GILD in Q1 2026 and held it in 1 quarter. The position peaked at $376K in Q1 2026. 2,272 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Oasis Advisors reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Oasis Advisors sold 2,700 Gilead Sciences shares in Q2 2026, an estimated $376K.
  • Oasis Advisors first reported a position in Gilead Sciences in Q1 2026 and held it in 1 quarter.
  • Oasis Advisors's Gilead Sciences position peaked at $376K in Q1 2026.
  • 2,272 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Oasis Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.